Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
McKesson
Chubb
Cipla
Deloitte
Harvard Business School
Baxter
Johnson and Johnson
Moodys

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,784,177

« Back to Dashboard

Which drugs does patent 6,784,177 protect, and when does it expire?

Patent 6,784,177 protects BIDIL and is included in one NDA.

This patent has four patent family members in four countries.
Summary for Patent: 6,784,177
Title: Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
Abstract:The present invention provides methods of treating and preventing mortality associated with heart failure in an African American patient with hypertension, and improving oxygen consumption, quality of life and exercise tolerance by administering a therapeutically effective amount of at least one hydralazine compound and at least one of isosorbide dinitrate and isosorbide mononitrate, and, optionally, one or more compounds, such as, for example, a digitalis, a diuretic compound, or a compound used to treat cardiovascular diseases. In the present invention, the hydralazine compound is preferably hydralazine or a pharmaceutically acceptable salt thereof. Preferred methods of the invention comprise administering hydralazine or a pharmaceutically acceptable salt thereof and isosorbide dinitrate.
Inventor(s): Cohn; Jay N. (Minneapolis, MN), Carson; Peter (Chevy Chase, MD)
Assignee: Nitro Med, Inc. (Bedford, MA)
Application Number:10/210,113
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery; Dosage form; Device;

Drugs Protected by US Patent 6,784,177

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Arbor Pharms Llc BIDIL hydralazine hydrochloride; isosorbide dinitrate TABLET;ORAL 020727-001 Jun 23, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial METHOD OF TREATMENT OF HEART FAILURE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,784,177

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,465,463 Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,784,177

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 7365900 ➤ Try a Free Trial
Canada 2383974 ➤ Try a Free Trial
European Patent Office 1212053 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 0117528 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Queensland Health
McKinsey
Chubb
Cantor Fitzgerald
Farmers Insurance
Healthtrust
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.